The relative teratogenic index and teratogenic potency: proposed components of developmental toxicity risk assessment.
Teratogenicity tests should provide answers to three questions: (1) Can the agent induce developmental defects? ("teratogenic potential"); (2) What are the effective doses? ("teratogenic potency"); and (3) Are effective doses below adult toxic doses? ("teratogenic hazard"). The answers to (2) and (3) should be quantitative in nature, but there are no accepted parameters to express these properties. In this paper we propose parameters for the description of teratogenic potency and hazard in quantitative terms. Derivation and calculation of the parameters are illustrated by the analysis of adult lethality and teratogenicity data of eight structurally related anhydrides and imides, following testing in the CD-1 mouse. Teratogenicity was evaluated following treatment on Days 8-10 of gestation, using an average of four dose groups per compound and at least 10 dams per group. Adult lethality was estimated following a similar 3-day dosage schedule with an average of 6 dose groups per compound and at least 8 animals per group. Dose-response relationships of teratogenicity were fitted to a probit model from which tD50 (median effective dose), and other effective doses were computed. It is proposed that tD05, as a minimum teratogenic dose, best represents teratogenic potency. In this study, potency ranged from 0.17 mmol/kg/day for phenytoin to 5.2 mmol/kg/day for ethosuximide. In order to measure teratogenic hazard a ratio between adult toxic (lethality was chosen as the most appropriate measure) and teratogenic responses was made. Since the dose-response slopes of lethality and teratogenicity were different, a simple ratio between median effective doses could not be used. It is shown that a ratio of LD01 to tD05 provides a "Relative Teratogenic Index" (RTI) which reflects the teratogenic hazard of a test agent. The following RTI values (LD01/tD05) were computed in this study: phthalic anhydride, 0.9; phensuximide, 1.0; succinic anhydride, 1.0; ethosuximide, 1.2; phenytoin, 1.6; phenacemide, 3.3; trimethadione, 4.0; and sodium valproate, 4.1. For these data, tD05 and RTI clearly represent the differing teratogenic potencies and hazards of the tested compounds. it is suggested that these parameters may be useful in comparative teratogenicity studies and may be valuable components of developmental toxicity risk assessment.